WALTHAM, Mass., Feb. 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. announced today that Lewis H. Bender, Chief Executive Officer will present at the BIO CEO & Investor Conference on Wednesday, February 13 at 2:00 p.m. ET in the Duke of Windsor Room at the Waldorf-Astoria, New York City.
A live webcast of the presentation can be viewed on Interleukin's website at www.ilgenetics.com. A replay will be posted on Interleukin's website approximately two hours after the event.
About Interleukin
Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual and quarterly reports and other documents filed with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
CONTACT: Media-Investors: Rich Tauberman of Financial Relations Board,
+1-201-964-2408
Web site: http://www.ilgenetics.com/
